$21.26
-0.31 (-1.44%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ANIK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
17 interventional · 13 with posted results
Held by 10 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., Man Group plc, +5 more) · FINRA short interest 4.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Integrity Implant System Post Market Clinical Follow-Up StudyNCT06741527Re-tear rate after rotator cuff augmentationOpen-label · Treatment | Not applicable | Recruiting | Device: Integrity Implant System | Rotator Cuff Tears of the Shoulder | 150 | Jun 2027 | ≤ 314 d | 2026-06-24 |
| HyaloFAST Trial for Repair of Articular Cartilage in the KneeNCT02659215Superiority of Hyalofast with Bone Marrow Aspirate Concentrate (BMAC) vs. Microfracture for % Change in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain ScoreRandomized · Single-masked · Treatment | Not applicable | Active, not recruiting | Device: Hyalofast · Procedure: Microfracture | Defect of Articular Cartilage | 200 | 2025-03-20actual | — | 2026-04-15 |
| Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)NCT02861183Change from baseline in elbow pain after grip as measured by a 100 mm Visual Analog Scale (VAS) at 12 weeks comparing the OVT group to the saline control groupRandomized · Double-masked · Treatment | Not applicable | Withdrawnsponsor's stated reason: Project was placed on hold indefinitely as the project resources were unavailable for this to move forward. | Device: OVT (Sodium Hyaluronate), Saline | Epicondylitis, Tennis Elbow, Epicondylosis | 0 | Apr 2027 | ≤ 253 d | 2022-11-30 |
| Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis PainNCT04231318results2023-08-09Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Cingal, Triamcinolone Hexacetonide (TH), Placebo | Osteoarthritis, Knee | 231 | 2022-05-16actual | — | 2023-08-09 |
| Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle JointNCT04640974results2024-03-07Numerical Rating Scale (NRS) Pain on WalkingOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Cingal | Osteoarthritis, Ankle | 25 | 2021-09-24actual | — | 2024-12-16 |
| Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip JointNCT04640298results2024-03-07Numerical Rating Scale (NRS) Pain on WalkingOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Cingal | Osteoarthritis, Hip | 25 | 2021-09-10actual | — | 2024-12-16 |
| Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder JointNCT04640961results2024-03-07Numerical Rating Scale (NRS) PainOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Cingal | Osteoarthritis, Shoulder | 25 | 2021-09-10actual | — | 2024-12-16 |
| MONOVISC for Hip Joint Pain Relief Due to OsteoarthritisNCT04204083results2025-01-28Numerical Rating Scale (NRS) Pain on WalkingOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Monovisc | Osteoarthritis, Hip | 25 | 2021-02-26actual | — | 2025-01-28 |
| MONOVISC for Shoulder Joint Pain Relief Due to OsteoarthritisNCT04204265results2025-01-28Numerical Rating Scale (NRS) PainOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Monovisc | Osteo Arthritis Shoulders | 25 | 2021-02-26actual | — | 2025-01-28 |
| MONOVISC for Ankle Joint Pain Relief Due to OsteoarthritisNCT04204278results2025-01-28Numerical Rating Scale (NRS) Pain on WalkingOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Monovisc | Osteoarthritis Ankle | 25 | 2021-02-26actual | — | 2025-01-28 |
| OVT for Epicondylosis (Tennis Elbow)NCT04026191The mean change in Elbow Pain from Baseline to 6 MonthsOpen-label · Treatment | Not applicable | Completed | Device: OrthoVisc®-T (OVT) | Epicondylitis, Lateral, Tendinopathy, Elbow | 50 | 2020-12-31actual | — | 2021-12-08 |
| Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow upNCT03390036results2023-05-31OMERACT-OARSI Responder Rate at 39 WeeksRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Combination product: Cingal · Device: Monovisc · Drug: Triamcinolone Hexacetonide | Knee Osteoarthritis | 526 | 2018-07-30actual | — | 2023-05-31 |
| Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone HexacetonideNCT03191903results2022-02-24Change From Baseline in WOMAC Pain Score at 26 Weeks (ITT Population)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Combination product: Cingal · Device: Monovisc · Drug: Triamcinolone Hexacetonide | Knee Osteoarthritis | 576 | 2018-04-23actual | — | 2022-02-24 |
| Repeat Injection of Cingal® for Osteoarthritis of the KneeNCT02381652results2020-09-03Number of Treatment-Emergent Adverse Events: Cingal 13-02 vs. Cingal 13-01Non-randomized · Open-label · Treatment | Phase 3 | Completed | Combination product: Cingal, Cingal, Cingal | Osteoarthritis of the Knee | 242 | Apr 2015actual | — | 2022-03-22 |
| Cingal Study for Knee OsteoarthritisNCT01891396results2022-05-12Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score Comparing Cingal® to Saline (ITT)Randomized · Double-masked · Treatment | Not applicable | Completed | Device: Hyaluronic Acid and TH (Cingal®), Hyaluronic Acid (Monovisc®), Saline | Knee Osteoarthritis | 368 | May 2014actual | — | 2023-06-01 |
| Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the KneeNCT00653432results2020-09-01Percentage of Subjects Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score (ITT) >=40% and 15 mm From Baseline Through 12 WeeksRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Monovisc® · Other: Saline | Osteoarthritis | 369 | Dec 2009actual | — | 2023-07-11 |
| Safety Study of Cosmetic Tissue Augmentation in People of ColorNCT01147172results2015-04-20Keloid Formation at Site of InjectionOpen-label · Treatment | Not applicable | Completed | Device: Elevess | Wrinkles | 100 | Dec 2009actual | — | 2017-10-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19